Nexavar (Bayer HealthCare) effective in patients with Non-Small Cell Lung Cancer

Nexavar (sorafenib tosylate), from Bayer HealthCare, was effective in patients with Non-Small Cell Lung Cancer and a KRAS mutation, but survival rates were reportedly "unsatisfactory," according to data presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy and Personalized Medicine. In the Phase II study, researchers assigned 57 patients with NSCLC and a KRAS mutation to 400 mg of Nexavar twice daily. At six weeks, Wouter W. Mellema, and his colleagues at the VU University Medical Center in Amsterdam, reported a rate of no progression of 52.6 percent. Fifteen patients stopped treatment before six weeks � 10 of whom stopped due to clinical progression. Median progression-free survival was 2.3 months, and median overall survival was 5.3 months. The researchers reported that 14 patients are still alive.